Compendia Bioscience

 Compendia Bioscience www.compendiabio.com
Life Technologies收购癌症发病前生物信息学公司Compendia Bioscience

 

ABOUT COMPENDIA BIOSCIENCE, INC.
Compendia Bioscience is dedicated to applying the global collection of cancer genomic data to impact patient treatment by enabling the discovery and development and better cancer diagnostics and treatments.

Compendia Bioscience is a growing, dynamic organization that brings together the many disciplines required to apply cancer genomic analysis to drug development, diagnostics and personalized medicine.

Our flagship product, Oncomine™, aggregates and analyzes the world’s growing collection of published genomic oncology data and provides practical, actionable views on the data and results. OncoPredictor™, our predictive biomarker discovery platform, performs comprehensive analyses to identify genomic biomarkers of in vitro drug response and importantly, predicts patient populations most likely to benefit from the drug. And lastly, our oncology companion diagnostics platform, Oncoscore™, leverages our extensive knowledge of the molecular diversity of cancer to provide deep molecular sub-typing of cancer patients. Our pharma and academic partners are now using Oncoscore to characterize clinical trial patient populations and devise predictors of therapy response.